OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Liu on Navigating the Frontline Treatment of ALK+ NSCLC

November 9th 2018

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses the frontline treatment of ALK-positive non–small cell lung cancer (NSCLC).

Dr. Ganjoo on Therapies for Patients With Uterine Leiomyosarcomas

November 9th 2018

Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses therapies for patients with uterine leiomyosarcomas.

Rationale for Regorafenib Combination Study in Pediatric Rhabdomyosarcoma

November 9th 2018

Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the rationale for a study of regorafenib (Stivarga) combinations in pediatric patients with rhabdomyosarcomas (RMS).

Dr. Weise Discusses the Future of Biosimilars in Oncology

November 9th 2018

Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses the future of biosimilars in oncology.

Dr. Strosberg Discusses Updates From the NETTER-1 Study

November 9th 2018

Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses updates from the NETTER-1 study in patients with neuroendocrine tumors (NETs).

Dr. Evans on the Tolerability of CDK4/6 Inhibitors in HR+ Breast Cancer

November 9th 2018

Terry L. Evans, MD, clinical assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the tolerability of CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

Dr. Bekaii-Saab on the Impact of Next-Generation Sequencing in mCRC

November 9th 2018

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the utility of next-generation sequencing in metastatic colorectal cancer (mCRC).

Dr. Tagawa Discusses Radiotherapy in Prostate Cancer

November 8th 2018

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses radiotherapy in the treatment of patients with prostate cancer.

Dr. Hill Discusses the Progression of CLL Treatment

November 8th 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the progression of treatment of patients with chronic lymphocytic leukemia.

Dr. Jagielska on Long-Term Survival With Lapatinib Plus Capecitabine in HER2+ Breast Cancer

November 8th 2018

Beata Jagielska, MD, PhD, internist, Centrum Medyczne Damiana Warsaw, discusses long-term survival with lapatinib (Tykerb) plus capecitabine in patients with HER2-positive breast cancer.

Dr. O'Donnell on Ongoing Immunotherapy Trials in Bladder Cancer

November 8th 2018

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses ongoing immunotherapy trials in bladder cancer.

Dr. Puhalla on the Value of Biosimilars in Oncology

November 8th 2018

Shannon L. Puhalla, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, medical oncologist and hematologist, UPMC Hillman Cancer Center, discusses the value of biosimilars in oncology.

Dr. Rini on Molecular Characteristics of the IMmotion151 Study in RCC

November 7th 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the molecular characteristics of patients with renal cell carcinoma (RCC) enrolled on the IMmotion151 study.

Identifying the Risk of Breast Cancer in Childhood Cancer Survivors

November 7th 2018

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses a study that is identifying the risk of breast cancer in survivors of childhood cancer.

Dr. Wang Discusses New Agents in the Field of MCL

November 7th 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses new agents in the field of mantle cell lymphoma (MCL).

Dr. Wong Discusses the FDA Approval of Elotuzumab Triplet in Myeloma

November 7th 2018

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses the FDA approval of elotuzumab (Empliciti) for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Rule on Patients With p53-Mutated MCL

November 7th 2018

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical Center, United Kingdom, discusses the treatment of patients with p53-mutated mantle cell lymphoma.

Dr. Rahman on Pertuzumab and Neratinib in HER2+ Breast Cancer

November 7th 2018

Mohammed J. Rahman, MD, oncologist, University of Pittsburgh Medical Center, discusses the roles of pertuzumab and neratinib in patients with HER2-positive breast cancer.

Dr. Brufsky Discusses Reasons to Use Biosimilars in Oncology

November 6th 2018

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses reasons to use biosimilars in oncology.

Dr. Ruddy on the Management of CNS Metastases in HER2+ Breast Cancer

November 6th 2018

Kathryn Ruddy, MD, associate professor of Oncology, Mayo Clinic, discusses the management of central nervous system (CNS) metastases in HER2-positive breast cancer.